Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Turning Point Therapeutics Inc.

https://tptherapeutics.com/

Latest From Turning Point Therapeutics Inc.

China Deal Watch: Four Biotechs Kick Off May With Multiple In/Out Deals

Four Chinese biotech companies reach in- and out-licensing deals covering antibody drug conjugates, small molecules and vaccines as they continue to pursue and develop innovation.

China Deals

Turning Point ROS1/TRK Inhibitor Repotrectinib Could Stand Out On Durability

The drug showed a high durability of response in ROS1-positive NSCLC patients, a factor that could give it significant differentiation compared with approved agents.

Cancer Business Strategies

Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor

Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.

Deal Watch Business Strategies

Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Approvals Complete Response Letters
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • TP Therapeutics, Inc
UsernamePublicRestriction

Register